drugset / Trial / NCT00275275

Pramipexole Conversion to Ropinirole Controlled Release (CR)

NCT00275275

Phase 3 Completed 61 enrolled Rajesh Pahwa, MD GlaxoSmithKline · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

A conversion study of Mirapex (pramipexole) to Requip (ropinirole) controlled release (CR) in patients with Parkinson's disease to determine the appropriate conversion ratio and side effects related to the drug.

Timeline

Start
2006-01
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ropinirole Small molecule
Background Pramipexole Unknown

Indications